Skip to main content

Research News

  • Nearly 700,000 people around the world die from colorectal cancer each year. Colorectal cancer is the second leading cause of cancer-related death in developed countries.  Anti-cancer therapies generally involve killing off tumor cells. A new study says, now the cancer cells can be turned back into normal tissue simply by reactivating a single gene.  The study is published in the Cell.

    [adsense:336x280:8701650588]

  • Australian researchers have developed a breakthrough vaccine-style therapeutic approach to treat rheumatoid arthritis, a debilitating disease affecting over 450,000 people in the country. Lead researcher Ranjeny Thomas from the University of Queensland's Diamantina Institute said results from the phase one clinical trial demonstrate the new treatment is safe and effective in supressing the immune response.

  • The research conducted by Dundee University, Scotland explained that the newly developed drug could work well against parasites resistant to current treatments of the mosquito-borne disease. Researchers  discovered a new compound, DDD107498 to treat malaria in a single dose, protects people from the disease and prevent the transmission of infection. The research is printed  in the journal 'Nature'.

  • An experimental drug from the US-based Eli Lilly and Company discovered to protect Alzheimer's-inflicted mice from memory deterioration, despite a high-glycemic-index (GI) diet meant to boost blood sugar levels. The experimental drug mimics the hunger-signaling hormone ghrelin.

  • Upto 3% of the global population suffering from Ankylosing spondylitis and two other debilitating conditions. Ankylosing spondylitis, a painful form of arthritis is an incurable immune disease affecting the spine, joints and tendons, and can be difficult to diagnose.

  • A new research suggests that a simple blood or urine test could soon identify men with an elevated, genetically-inherited risk for the disease. The study is available online and will be published in an upcoming issue of the journal Cancer Discovery.

  • India and the European Union will soon begin research on health with focus on 'Diagnostics and interventions in chronic non-communicable diseases'.  Main aim behind this collaboration is to support high quality research and development of tools and technologies for the diagnostics of chronic non-communicable diseases; research and innovation within interventions for chronic non-communicable diseases; and mechanisms in chronic non-communicable diseases. This will strengthen scientific, technology and business collaborations between Europe and India.

  • Savitribai Phule Pune University’s department of Interdisciplinary School of Health Sciences and Institute of Bioinformatics and Biotechnology have proved that Triphala, a widely used ayurvedic formulations, effective  against a wide range of diseases like cardiovascular diseases, asthma, arthritis, diabetes and cancer. The team of scientists Uma Chandran, Neelay Mehendale, Girish Tillu and Prof. Bhushan Patwardhan used a technique known as poly-pharmacology. Triphala formulation as a whole contains 174 bioactives.

  • A study led by researchers at Case Western Reserve and UT Southwestern Medical Center  showed An experimental drug  help by regrow damaged liver, colon and bone marrow tissue in laboratory mice.  Now scientist trying to work in humans. However, experts cautioned that their research is at a very early stage, and more work is needed before it can be tested in humans. This experimental drug is now known only as SW033291. It can shut down the activity of a gene product found in all humans, 15-hydroxyprostaglandin dehydrogenase (15-PGDH), that in turn allows room for more prostaglandin E2, which encourages many types of tissue stem cells to grow and promotes healing.

Subscribe to Research News